|
Nochmal die letzen Zahlen aus 2006. Denke wir könnten dem Trend entsprechend auch die Zahlen für das Jahresende 2006 bekommen. Sehe für Synbiotics eine rosige Zukunft (natürlich auf für Aktie) ................ ................ San Diego, California: August 21, 2006 � Synbiotics Corporation today announced that it recorded a 7 percent increase in revenues for the first six months of 2006 compared with the same period in 2005. Revenues for the first six months totaled $10,815,000 compared with $10,140,000 for the same period last year. Sales growth was lead by the company�s avian influenza line. Paul Hays, Synbiotics' President and Chief Executive Officer, said, �Our flu portfolio has demonstrated that Synbiotics is a leader in the area of flu diagnostics. Our Flu Detect� avian influenza type A antigen test strip and ProFLOK� AIV Plus avian influenza antibody ELISA test kits have been well received by poultry producers, veterinary diagnostic laboratories and public health organizations throughout the world.� Operating expenses for the first half year 2006 were significantly reduced due to savings realized through costs spared as a result of key efforts implemented in 2005 including: the company now being private, the restructuring of debt and the reorganization within French affiliate, Synbiotics Europe SAS. "We are very pleased with our results. Clearly the programs we implemented in 2005 have achieved the intended result,� Hays said. Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the poultry, livestock and companion animal markets worldwide. Synbiotics manufactures and distributes its products through its operations in San Diego, California, and Lyon, France. For information on Synbiotics and its products, visit the Company�s website at www.synbiotics.com. With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors and possible technology improvements by others. These forward-looking statements represent Synbiotics Corporation's judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements. |
|
| aus der Diskussion: | SYNBIOTICS CORP |
| Autor (Datum des Eintrages): | GoldenStock (13.03.07 21:02:53) |
| Beitrag: | 49 von 93 (ID:28279828) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |